PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that the following clinical and preclinical
abstracts are expected to be the subject of oral or poster presentations at
the Annual Meeting of the American Association for Cancer Research (AACR),
being held April 12-16, 2008 in San Diego:
-- "Dendritic and T cell functions in patients with metastatic hormone-
refractory prostate cancer treated with GVAX immunotherapy for prostate
cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)
- Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m.
-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent
induction of CD8+ T cell activation and clinical responses" (Abstract
#2539, Clinical Immunotherapy Session) - Oral presentation scheduled
for Monday, April 14, 2008 at 1:40 p.m.
-- "Increased doses of an anti-CD30 antibody, MDX-060, results in
prolonged progression free survival in subjects with CD30 positive
lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,
Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for
Wednesday, April 16, 2008 at 8:00 a.m.
-- "Preclinical development of anti B7-H4 therapeutic antibodies"
(Abstract #4986, Developmental Immunotherapy Session) - Oral
presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m.
-- "Human antibody conjugates of potential utility for prostate cancer
therapy: a comparison of MGBA conjugates with antibodies targeting a
cell surface target (prostate-specific membrane antigen) and an extra-
cellular target (Mindin/RG1)" (Abstract #4062, Immunoconjugates,
Peptides, and Protein Therapeutics Session) - Poster session scheduled
for Tuesday, April 15, 2008 at 8:00 a.m.
-- "Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate"
(Abstract #4061, Immunoconjugates, Peptides, and Protein Therapeutics
Session) - Poster session scheduled for Tuesday, April 15, 2008 at 8:00
a.m.
-- "Mechanism of activation of a human anti-CD70 antibody-MGBA conjugate
and efficacy in a nude rat model of renal carcinoma" (Abstract #4057,
Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster
session scheduled for Tuesday, April 15, 2008 at 8:00 a.m.
-- "Ptk7 as a direct and tumor stroma target in multiple solid
malignancies" (Abstract #1526, Targets and Screening Approaches
Session) - Poster session scheduled for Sunday, April 13, 2008 at 1:00
p.m.
Abstracts and information about the AACR and its Annual Meeting may be
found at http://www.aacr.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, Ext. 2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, Ext. 2221, both of
Medarex, Inc.
|
